Teva’s COPAXONE® 40mg – Favorable Response from European Patent Office

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that a three-member panel of the European Patent Office’s (EPO) Opposition Division upheld patent EP 2 949 335 covering Teva’s COPAXONE® 40mg product in Europe. The Opposition Division will issue its written underlying rationale on the decision within a few months.

COPAXONE® is a highly complex molecule for which consistent proprietary manufacturing methods are required. These determine the composition, purity and batch-to-batch consistency of COPAXONE®. The patent protects the three-times-weekly subcutaneous injection of 40 mg/mL (“40mgTIW”) of glatiramer acetate for the treatment of certain forms of multiple sclerosis.

https://www.marketscreener.com/TEVA-PHARMACEUTICAL-INDUS-56537293/news/Teva-s-COPAXONE-40mg-Favorable-Response-from-European-Patent-Office-Teva-Pharmaceutical-Industri-28399087/